KSP

THE PHAGE is a medical device company specializing in the development of artificial intelligence technology aimed at predicting postprandial blood glucose levels. The company focuses on analyzing biometric data and daily activities to provide personalized health insights. Its platform delivers AI-driven recommendations for managing blood glucose levels after meals, empowering individuals to make informed lifestyle choices and enhance their overall health management. Through its innovative approach, THE PHAGE seeks to improve the quality of life for those monitoring their blood glucose levels.

Thermalytica focuses on the research, development, and consulting services related to heat insulating and heat shielding materials. The company provides a range of products aimed at addressing energy efficiency and environmental challenges, including thermal insulation materials that significantly reduce energy loss and environmental impact. Additionally, Thermalytica offers specialized equipment for electron beam physical vapor deposition and thermal barrier coating, catering to industries such as construction, manufacturing plants, and home appliances. The company also delivers ultra-high temperature thermal barrier coating services essential for hydrogen-fired power generation, facilitating advanced thermal control technologies to support sustainable energy solutions.

Mira Robotics, Inc. is a Japanese company based in Kawasaki City that specializes in designing and developing a Robot as a Service (RaaS) platform. Founded in 2018, the company offers a range of services including robot development, robot intelligence, and cloud collaboration, enabling robots to be utilized in various fields. Through its innovative approach, Mira Robotics aims to enhance the functionality and accessibility of robotic technologies for diverse applications.

Melody International is a manufacturing company that specializes in developing medical equipment for remote medical services. The company has created a fetal monitoring device designed to assist healthcare providers during challenging delivery situations. This device includes a fetal heart monitor, a uterine contraction monitor, and a tablet interface, which features a built-in speaker in the transducer connected via the internet. The system also functions as a fetal doppler, allowing women to monitor both maternal and fetal health conditions from distant locations. Through its innovative technology, Melody International aims to enhance access to essential medical care in remote areas.

Metcela Inc., founded in 2016 and based in Kawasaki-shi, Japan, is a clinical-stage biotech company focused on developing innovative therapies for cardiac diseases. The company specializes in fibroblast-based treatments, particularly utilizing VCAM-1-positive Cardiac Fibroblasts (VCF). Metcela's lead asset, MTC001, aims to repair damaged heart tissues and reestablish a favorable microenvironment by enhancing the healing capabilities of the patient's own cells. This approach provides an alternative treatment option for heart disease, offering patients an effective and cost-efficient solution for conditions like heart failure.

AdipoSeeds is a biotechnology company focused on addressing the global shortage of platelets by developing an innovative system for platelet production. Utilizing a novel technology, the company generates platelets from mesenchymal stem cells without the need for complex and expensive gene transfer methods. This advancement aims to establish a reliable blood supply system that offers affordable and safe platelet-related treatments. AdipoSeeds' approach not only facilitates the creation of fat-derived platelets for blood products but also enhances applications in wound care medicine, thereby contributing to improvements in medical practices and patient care.

Luxonus is a medical device manufacturing company that specializes in developing innovative imaging technology using photoacoustic methods. The company's core product is a diagnostic device that utilizes optical ultrasonic technology to capture ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. This imaging approach allows for safe and non-invasive detection and diagnosis of diseases, providing healthcare professionals with a comprehensive understanding of disease onset, healing processes, and health conditions before and after illness. By combining light and ultrasonic waves, Luxonus aims to enhance medical imaging capabilities and improve patient outcomes.

Ampametry provides neuropsychiatric drugs with AMPA-PET technology. They offers central nervous system drug discovery business AMPA-PET technology.

Integral Geometry Science Inc. is a Japanese company founded in 2012, based in Kobe, that specializes in the design and development of advanced measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic fields and scattered fields, creating innovative solutions such as a microwave mammography system that effectively addresses the challenges of imaging high-density breast tissue. This technology provides clear images that aid healthcare professionals in accurately distinguishing between cancerous and non-cancerous tissue, significantly reducing the need for painful and radiation-exposing conventional screening methods. Additionally, Integral Geometry Science manufactures nondestructive inspection systems for lithium-ion batteries, further expanding its expertise in measurement systems.

iXs is a start-up focused on addressing social challenges through innovative robotic technology. The company specializes in the development of AI-integrated robots aimed at performing maintenance inspections across various sectors, including roads, construction, iron and steel, electronics manufacturing, housing, and electric power. iXs engages in commissioned and joint development projects to enhance the quality of inspections on large infrastructure projects while minimizing the workloads of human operators. In addition to robot development, iXs has created AI and data service systems to analyze big data, providing comprehensive support from product introduction to operational implementation. This approach enables the company to deliver effective solutions tailored to meet customer needs.

Integral Geometry Science Inc. is a Japanese company founded in 2012, based in Kobe, that specializes in the design and development of advanced measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic fields and scattered fields, creating innovative solutions such as a microwave mammography system that effectively addresses the challenges of imaging high-density breast tissue. This technology provides clear images that aid healthcare professionals in accurately distinguishing between cancerous and non-cancerous tissue, significantly reducing the need for painful and radiation-exposing conventional screening methods. Additionally, Integral Geometry Science manufactures nondestructive inspection systems for lithium-ion batteries, further expanding its expertise in measurement systems.

StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006, specializing in the development of regeneration-guided medicines for treating intractable diseases. The company focuses on innovative research and development of therapies that mobilize stem cells within the body to promote healing in various conditions, including epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM offers a range of products, including regeneration-inducing peptides and proteins, as well as therapeutic autologous cell collection devices and stem cell gene therapy technologies. The company aims to advance regenerative medicine by creating treatments that facilitate functional tissue regeneration without the need for external stem cell extraction.

Miraikikai, Inc. is a Japanese company specializing in the development, manufacturing, distribution, and maintenance of robotics and mechatronics products. Founded in 2004 and based in Takamatsu, Japan, the company originated from Kagawa University and aims to create intelligent mobile robots for professional use. Its product offerings include solar cleaning robots that utilize advanced artificial intelligence to efficiently clean solar panels at utility-scale plants without water, employing brushes and air blowers to remove dust and sand. Additionally, Miraikikai develops 3D Laser Sensors for various applications and provides technical consultation and development solutions, leveraging extensive research and experience in mechanical design and control technology to deliver high-quality, cost-effective solutions.

Metcela Inc., founded in 2016 and based in Kawasaki-shi, Japan, is a clinical-stage biotech company focused on developing innovative therapies for cardiac diseases. The company specializes in fibroblast-based treatments, particularly utilizing VCAM-1-positive Cardiac Fibroblasts (VCF). Metcela's lead asset, MTC001, aims to repair damaged heart tissues and reestablish a favorable microenvironment by enhancing the healing capabilities of the patient's own cells. This approach provides an alternative treatment option for heart disease, offering patients an effective and cost-efficient solution for conditions like heart failure.

Renascience is a research and development firm focused on creating innovative medical solutions to address various health challenges. The company employs a range of modalities, including pharmaceuticals, medical devices, and artificial intelligence, to develop treatments and enhance patient care. By combining advanced research techniques with practical applications, Renascience aims to improve medical outcomes and contribute to the advancement of healthcare.

Cyfuse Biomedical K.K., established in 2010 with headquarters in Tokyo, Japan, specializes in the research, development, and commercialization of tissue fabrication systems and cell-based products on a global scale. The company's core business involves creating and selling advanced 3D BioFabrication systems along with associated consumables. These systems automate the assembly of cells into complex 3D structures, enabling researchers to explore various cell delivery strategies. Cyfuse Biomedical also develops and licenses 3D tissue products for therapeutic applications and drug development purposes, spanning blood vessel grafts for hemodialysis patients or coronary bypasses, cardiac grafts for drug screening or myocardial infarction therapy, cartilage grafts for reconstructive surgeries, and hepatocyte grafts for drug metabolism studies or hemophilia treatment. Additionally, the company offers contract manufacturing services for 3D tissue products tailored to research needs. Its primary clientele comprises research institutions and universities worldwide.

StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006, specializing in the development of regeneration-guided medicines for treating intractable diseases. The company focuses on innovative research and development of therapies that mobilize stem cells within the body to promote healing in various conditions, including epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM offers a range of products, including regeneration-inducing peptides and proteins, as well as therapeutic autologous cell collection devices and stem cell gene therapy technologies. The company aims to advance regenerative medicine by creating treatments that facilitate functional tissue regeneration without the need for external stem cell extraction.

CODE Meee Inc., established in 2017 and headquartered in Yokohama, Japan, is a comprehensive scent production company. It offers tailored scent solutions to both individuals and businesses, including optimal scent recommendations based on data analysis, fragrant product planning, and manufacturing services. The company operates a fragrance branding and marketing platform that provides personalized aroma subscriptions, focusing on mental health benefits such as stress reduction and mood enhancement.

Rena Therapeutics Inc. is a biopharmaceutical company based in Tsukuba, Japan, specializing in the development of nucleic acid medicines aimed at treating various types of cancer and intractable diseases. Founded in January 2015, the company focuses on utilizing its proprietary Hetero-Duplex oligonucleotides technology to create novel drug delivery systems that target tumors more effectively than conventional drugs. Rena Therapeutics aims to address unmet medical needs by offering treatments for a range of conditions, including glioma, melanoma, acute and chronic leukemias, and lymphomas. The advantages of nucleic acid drugs, such as the ability to specifically target intracellular drug molecules and minimize side effects, position the company at the forefront of innovative therapeutic solutions in the pharmaceutical market.

Spectronix is a company dedicated to the development of innovative laser technologies and applications, specifically tailored for microprocessing and microfabrication. By focusing on advancements in laser technology, Spectronix aims to enhance manufacturing processes, offering faster processing speeds that vary according to the materials used. This efficiency allows manufacturers to achieve competitive pricing and reduced operational costs, positioning Spectronix as a key player in the laser technology sector.

Z-Works Inc. is a Tokyo-based technology company specializing in Internet of Things (IoT) solutions. Established in 2015, it develops a range of IoT devices, including sensors for monitoring, fire alarms, smart locks, and smart meters. The company also offers consulting services for proof of concept, as well as sensor packages tailored for specific applications. Its flagship product, the Z-Works Life Engine, is a cloud-based IoT platform that collects and analyzes data from devices equipped with communication protocols. This platform enables users to access data remotely via smartphones, facilitating improved care for elderly individuals in various settings, including care facilities and home environments. By providing innovative IoT solutions, Z-Works aims to alleviate the challenges faced by caregivers and enhance the quality of life for users.

Spectronix is a company dedicated to the development of innovative laser technologies and applications, specifically tailored for microprocessing and microfabrication. By focusing on advancements in laser technology, Spectronix aims to enhance manufacturing processes, offering faster processing speeds that vary according to the materials used. This efficiency allows manufacturers to achieve competitive pricing and reduced operational costs, positioning Spectronix as a key player in the laser technology sector.

Kringle Pharma, Inc. is a biopharmaceutical company based in Ibaraki, Japan, founded in 2001. The company specializes in the research and development of hepatocyte growth factor (HGF) protein medicines, which have regenerative healing properties for liver cells and other organs. Kringle Pharma focuses on creating HGF products aimed at treating a range of conditions, including acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury associated with ALS, and vocal fold scars. Additionally, the company explores the therapeutic potential of NK4, a bi-functional molecule that acts as an HGF-antagonist with antiangiogenic properties, targeting cancer therapies. Kringle Pharma's innovative approach positions it at the forefront of developing treatments for intractable diseases.

Starsphere is a developer of a cloud-based Electronic Data Capture (EDC) system that focuses on transforming data collection, analysis, and utilization in the life sciences sector. The company's platform is designed to enhance IT services primarily for the healthcare industry, aiming to improve the efficiency and safety of medical treatments. By leveraging advanced technologies, Starsphere strives to enable healthcare professionals to deliver more effective and safer treatments to patients in a timely manner, aligning with its vision of advancing healthcare outcomes.

Stem Cell & Device Laboratory, Inc. is a research and development company based in Kyoto, Japan, focused on the manufacturing and sale of cells, devices, and integrated products that utilize cell materials for drug discovery applications. Founded in 2014, the company specializes in developing innovative scaffold materials that demonstrate functional and cell compatibility, particularly for studies involving pluripotent stem cells. By leveraging advanced micro-engineering and nanofabrication technologies, Stem Cell & Device Laboratory aims to contribute to advancements in cell application products that support the health and well-being of society.

Ipoca Inc. is a Tokyo-based company that develops a mobile application designed to enhance the shopping experience by allowing users to store information about specific stores. Established in 2007, Ipoca provides a digital solution for retail and distribution companies, offering an in-store information platform that connects consumers with local businesses. The company's technology leverages smartphone-based behavior data, including location information, online search results, and purchase history, to help clients attract new customers and improve customer retention. By facilitating better connections between consumers and their communities, Ipoca aims to contribute to the revitalization of both local and national economies in Japan.

Nanoegg is aiming to create a medical breakthrough from skin research and to realize medical care without the use of needles.

Fileforce is a Tokyo-based company, founded in 2001, that specializes in providing secure and scalable cloud file services for businesses and enterprises of all sizes. The company offers a robust platform that enables enterprises to safely store, manage, access, and share files from various devices, including computers, tablets, and smartphones. Fileforce's services are designed to protect valuable information and assets, facilitating efficient management of business activities such as proposals, quotations, and design documents. By enabling effective file-sharing and organization, Fileforce supports corporations in optimizing their operational workflows and enhancing collaboration.

TMS Co., Ltd., established in 2005 and headquartered in Tokyo, Japan, is a clinical-stage biotechnology company. It specializes in developing drug candidates and medical technologies derived from academic research. TMS focuses on a unique group of small molecule compounds, known as SMTPs, which exhibit both thrombolytic and anti-inflammatory properties. The company's lead compound, TMS-007, is currently in a Phase IIa clinical trial for the treatment of acute ischemic stroke, in partnership with Biogen.

Rena Therapeutics Inc. is a biopharmaceutical company based in Tsukuba, Japan, specializing in the development of nucleic acid medicines aimed at treating various types of cancer and intractable diseases. Founded in January 2015, the company focuses on utilizing its proprietary Hetero-Duplex oligonucleotides technology to create novel drug delivery systems that target tumors more effectively than conventional drugs. Rena Therapeutics aims to address unmet medical needs by offering treatments for a range of conditions, including glioma, melanoma, acute and chronic leukemias, and lymphomas. The advantages of nucleic acid drugs, such as the ability to specifically target intracellular drug molecules and minimize side effects, position the company at the forefront of innovative therapeutic solutions in the pharmaceutical market.

Megakaryon Corporation is a medical research company based in Kyoto, Japan, with an additional office in Tokyo. Founded in 2011, the company specializes in developing innovative blood products, specifically platelets and red blood cells, from human induced pluripotent stem (iPS) cell lines. Megakaryon's technology focuses on transfusion medicine, enabling the production of platelets without reliance on traditional blood donations. This approach aims to enhance clinical applications and provide medical practitioners with the ability to manage and maintain patients' platelet counts effectively.

BrightPath Biotherapeutics Co., Ltd. is a biopharmaceutical company based in Kurume, Japan, specializing in the development of innovative cancer immunotherapy drugs. The company is advancing its lead candidate, ITK-1, a cancer peptide vaccine currently in Phase III clinical trials for the treatment of prostate cancer. Additionally, BrightPath is developing GRN-1201, which is in Phase II trials for non-small cell lung cancer and Phase I trials for melanoma. The company also has research-stage products, including GRN-1301, a neoantigen targeting drug-resistant tumors in non-small cell lung cancer, and iPS-NKT, a therapy utilizing induced pluripotent stem cell-derived NKT cells. Founded in 2003, BrightPath Biotherapeutics aims to stimulate potent immune responses to tumor-associated antigens through its peptide vaccine technology.

REGiMMUNE Corporation is a biotechnology company based in Tokyo, Japan, with an additional office in San Francisco, California. Founded in 2006, the company specializes in the discovery and development of immune-regulatory therapeutics aimed at treating severe diseases and disorders related to the immune system. Utilizing its proprietary reVax technology, REGiMMUNE targets immune tolerance by inducing regulatory T cells, which can address a variety of conditions such as Graft versus Host Disease, type 1 diabetes, rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. The company has one clinical-stage compound, RGI-2001, currently in a Phase I/II trial for GvHD associated with hematopoietic stem cell transplantation, and a second product, RGI-3001, in preclinical development for type 1 diabetes. With a pipeline that includes several promising compounds, REGiMMUNE aims to provide innovative treatments that minimize the side effects commonly associated with traditional immunosuppressants.

Ipoca Inc. is a Tokyo-based company that develops a mobile application designed to enhance the shopping experience by allowing users to store information about specific stores. Established in 2007, Ipoca provides a digital solution for retail and distribution companies, offering an in-store information platform that connects consumers with local businesses. The company's technology leverages smartphone-based behavior data, including location information, online search results, and purchase history, to help clients attract new customers and improve customer retention. By facilitating better connections between consumers and their communities, Ipoca aims to contribute to the revitalization of both local and national economies in Japan.

Connectec Japan Corporation specializes in the development of semiconductor and electrical products, focusing on semiconductor chip bonding and low-temperature MEMS chips. Founded in 2009 and headquartered in Myoko, Japan, the company also offers foundry services for semiconductor packaging, alongside technical support for surface mount technology (SMT). Its capabilities extend to providing evaluation, analysis, and reliability testing services, as well as developing small desktop semiconductor assembly equipment. Connectec Japan operates a satellite office in Kyoto and has sales offices in Seoul, South Korea, and Suzhou, China, serving a diverse clientele in various industrial applications.